Form 4: GoodRx CFO Karsten Voermann Executes Stock Transactions
SEC Form 4 Filing
GoodRx's Chief Financial Officer, Karsten Voermann, engaged in stock transactions involving the vesting of restricted stock units and the subsequent sale of shares to cover tax obligations.
Summary
- Karsten Voermann, the Chief Financial Officer of GoodRx Holdings, Inc., executed transactions involving Class A Common Stock on December 8, 2024.
- These transactions included the vesting of 54,064 restricted stock units, each representing a contingent right to receive one share of Class A common stock.
- Following the vesting, 24,659 shares were sold at a price of $4.91 per share to cover tax obligations.
- After these transactions, Voermann directly owns 303,304 shares of Class A Common Stock and 378,448 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by a company executive. It does not contain any information that would be considered positive or negative from an investment perspective.
Industry Context
This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the vesting schedule of equity awards and the subsequent sale of shares to cover tax liabilities.
Comparison to Industry Standards
- The vesting schedule of the restricted stock units, with an initial vesting of 6.25% followed by quarterly installments, is a common practice in the tech industry for executive compensation.
- The sale of shares to cover tax obligations is a standard procedure for executives receiving equity compensation.
- The reporting of these transactions via SEC Form 4 is a mandatory requirement for company insiders.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are related to executive compensation and do not indicate a change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 12/08/2022 | Initial vesting date of 6.25% of the restricted stock units. |
| 12/08/2024 | Date of stock transactions including vesting of restricted stock units and sale of shares. |
| 12/09/2024 | Date of signature for the SEC Form 4 filing. |
Keywords
GoodRx, GDRX, Karsten Voermann, CFO, stock transaction, restricted stock units, Class A Common Stock, insider trading, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.